Business Model: Our business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. We have an established influenza vaccine licensing business. Our revenue comes from licence fees and royalties on sales.
Our lead asset, the LAIV (Live Attenuated Influenza Virus) vaccine technology, is used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Nasovac-S™ is based on BioDiem’s technology and is already marketed in India; our licencee in China completed their Phase III clinical trials in 2017.
Our antimicrobial in development, BDM-I, is a synthetic compound targeting the treatment of infections, including antibiotic-resistant infections. BDM-I is active against a range of disease-causing microbes. Key patents have been granted worldwide. BioDiem has benefited from work conducted by major research institutions in the United States that have undertaken studies of BDM-I. BDM-I is in the preclinical stage of development and is being commercialised through our subsidiary, Opal Biosciences Ltd (www.opalbiosciences.com). Opal Biosciences seeks investment to develop its antimicrobial products.
Our lead product is the Live Attenuated Influenza Virus (LAIV) technology, which has been used to develop a novel intranasal vaccine for the prevention of seasonal and pandemic influenza. The technology is licensed to BioDiem by the Institute of Experimental Medicine (IEM) in St Petersburg, Russia.
Egg-based production: The version of the LAIV vaccine that uses chicken eggs for production is licensed to the World Health Organization for use in developing countries as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. This allows governmental and non-governmental organisations or private companies in those territories to produce seasonal and pandemic vaccines using eggs. In 2014 the egg-manufactured LAIV vaccine was launched in India as Nasovac-S™ for protection against seasonal influenza. Phase III clinical trials have been completed in China in 2017. The LAIV technology is currently available for licence from BioDiem for additional markets.
Cell-based production: A version of the vaccine which can be grown in tissue culture has completed first-in-human and proof-of-concept clinical trials in Europe as part of development for European registration. This technology is currently available for licence from BioDiem.
To request further information on the LAIV technology, please contact email@example.com.
Development of the antimicrobial BDM-I
The continued rise in antibiotic-resistant strains of bacteria such as MRSA, tuberculosis and gonorrhoea, and the increasing problem of clinical fungal infections, has led to significant interest in compounds which may address the lack of treatment options.
BDM-I is a novel compound which has shown impressive activity in screening studies against a range of pathogenic micro-organisms including vancomycin-resistant Staph aureus and Neisseria gonorrhoea, as well as a selection of pathogenic fungi including Scedosporium spp. BDM-I is being developed in BioDiem’s subsidiary, Opal Biosciences. For more information see http://www.opalbiosciences.com
BioDiem’s other programs